Trial Profile
Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix and Prevnar, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune at 3 to 5 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Hib-meningococcal vaccine groups C and Y conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib vaccine conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 23 Jul 2012 Status changed from active, no longer recruiting to completed.
- 01 Jan 2010 Results published in the Pediatric Infectious Disease Journal.
- 19 Nov 2007 Status change from in progress to completed.